Page 5 - HFA Dateline 2020-2021 Special Issue

B:9"
T:8.5"
S:7.5"

When the temperature rises above 86˚F
Esperoct has you covered
®
a

The EHL product with the highest storage temperature for the longest time

Be prepared with

Proven protection against bleeds High factor levels from one dose to the next
in adults and adolescents in adults and adolescents c

• 1.2 overall bleeds per year b • At or above 3% trough level for 100% of the time d
• At or above 5% trough level for 90% of the time e
EHL=extended half-life.
a For up to 3 months.
b 175 previously treated patients with severe hemophilia A received Esperoct 50 IU/kg every 4 days for 76 weeks based on median annualized bleed rates shown.
®
c Trough level goal is 1% for prophylaxis.
®
d Data shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct 50 IU/kg every 4 days for
76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
e Steady-state FVIII activity levels were estimated in 143 adults and adolescents using pharmacokinetic modeling.
What is Esperoct ? What should I tell my healthcare provider before
®
Esperoct [antihemophilic factor (recombinant), using Esperoct ?
®
®
glycopegylated-exei] is an injectable medicine to treat • Before taking Esperoct , you should tell your healthcare S:9.875" T:11" B:11.5"
®
and prevent or reduce the number of bleeding episodes provider if you have or have had any medical conditions,
in people with hemophilia A. Your healthcare provider take any medicines (including non-prescription
may give you Esperoct when you have surgery medicines and dietary supplements), are nursing,
®
• Esperoct is not used to treat von Willebrand Disease pregnant or planning to become pregnant, or have
®
been told that you have inhibitors to factor VIII
IMPORTANT SAFETY INFORMATION • Your body can make antibodies called “inhibitors”
Who should not use Esperoct ? against Esperoct , which may stop Esperoct from
®
®
®
• You should not use Esperoct if you are allergic to factor working properly. Call your healthcare provider
®
VIII or any of the other ingredients of Esperoct or if right away if your bleeding does not stop after
®
you are allergic to hamster proteins taking Esperoct ®

What is the most important information I need to What are the possible side effects of Esperoct ?
®

know about Esperoct ? • Common side effects of Esperoct include rash or
®
®
• Do not attempt to do an infusion yourself unless you itching, and swelling, pain, rash or redness at the
have been taught how by your healthcare provider location of infusion
or hemophilia treatment center Please see Brief Summary of Prescribing Information
• Call your healthcare provider right away or get on the following page.
emergency treatment right away if you get any
signs of an allergic reaction, such as: hives, chest

tightness, wheezing, dizziness, difficulty breathing, Discover more at Esperoct104.com.

and/or swelling of the face
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro,
New Jersey 08536 U.S.A.
®
Esperoct is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk Printed in the U.S.A.
US20ESP00151 March 2021

PREPARED BY
11509657 Patient Journal Ad M4

Job info Images Fonts Special Instructions
Date: 2-17-2021 2:46 PM NOVO_A059989_4C.tif (CMYK; 1176 ppi, -1177 Apis (Bold, Black, Regular), Frutiger LT Std (67 No KO type smaller than 6 pt.; standard SWOP
Client: NOVO NORDISK INC ppi; 51%, -51%; 101.7MB), NOVO_A059987_4C. Bold Condensed, 57 Condensed) specs; flatten transparenciesMinimum of 300 dpi
Product: PATIENT CHANNEL tif (CMYK; 1179 ppi; 46.19%; 113.9MB), for half tone times, 600 dpi for images containing
Client Code: US20ESP00151 NOVO_A059985_4C.tif (CMYK; 1697 ppi; Additional Information
WF Issue # 8135845 17.67%; 99.9MB), ESP_US_RM_H_4CP_FC_Pos. None
Releasing as: Other ai (44.59%; 921KB), nn_logo_cmyk_blue.
Final Size: None ai (10.76%; 75KB), 104_violater.ai (20.19%;
Finishing: None 991KB)
Gutter: None Inks Additional Comments for Sizing
Colors: 4/C Cyan, Magenta, Yellow, Black None
Team
Producer: None
AD: Emma
AE: Breanne Murphy Scale: 1" = 1"
QC: None Bleed
Production: Debi Post ext 2208 Trim/Flat 9" w x 11.5" h 9" w x 11.5" h
Digital Artist: McAuliffe, Aly (PPY-FCR) Live/Safety 8.5" w x 11" h 8.5" w x 11" h
FR Spellcheck: None 7.5" w x 9.875" h 7.5" w x 9.875" h
Path: PrePress:Novo_Nordisk:Esperoct:11509657:11509657_Patient_Journal_Ad_M4FR.indd
_ _